MX2024009773A - Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso. - Google Patents

Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso.

Info

Publication number
MX2024009773A
MX2024009773A MX2024009773A MX2024009773A MX2024009773A MX 2024009773 A MX2024009773 A MX 2024009773A MX 2024009773 A MX2024009773 A MX 2024009773A MX 2024009773 A MX2024009773 A MX 2024009773A MX 2024009773 A MX2024009773 A MX 2024009773A
Authority
MX
Mexico
Prior art keywords
diphenyldiazole
methods
derivatives
pharmaceutical composition
composition including
Prior art date
Application number
MX2024009773A
Other languages
English (en)
Spanish (es)
Inventor
Armin Giese
Johannes Levin
Vesco Emanuela Del
Original Assignee
Modag Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modag Gmbh filed Critical Modag Gmbh
Publication of MX2024009773A publication Critical patent/MX2024009773A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2024009773A 2022-03-01 2023-03-01 Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso. MX2024009773A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22159408 2022-03-01
PCT/EP2023/055160 WO2023166045A1 (en) 2022-03-01 2023-03-01 Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use

Publications (1)

Publication Number Publication Date
MX2024009773A true MX2024009773A (es) 2024-08-19

Family

ID=80623476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009773A MX2024009773A (es) 2022-03-01 2023-03-01 Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso.

Country Status (12)

Country Link
US (1) US20250161273A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486340A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508912A (cg-RX-API-DMAC7.html)
KR (1) KR20240155237A (cg-RX-API-DMAC7.html)
CN (1) CN118715010A (cg-RX-API-DMAC7.html)
AU (1) AU2023227368A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246018A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002379A1 (cg-RX-API-DMAC7.html)
IL (1) IL314952A (cg-RX-API-DMAC7.html)
MX (1) MX2024009773A (cg-RX-API-DMAC7.html)
PE (1) PE20250781A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023166045A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024349468A1 (en) 2023-09-26 2026-04-16 Teva Pharmaceutical Industries Ltd. Emrusolmin for use in treating multiple system atrophy
KR20250090047A (ko) * 2023-12-12 2025-06-19 가천대학교 산학협력단 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물
WO2026139903A1 (en) 2024-12-23 2026-07-02 Teva Pharmaceutical Industries Ltd. Solid state forms of emrusolmin and process for preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2714453T3 (es) * 2008-06-09 2019-05-28 Univ Muenchen Ludwig Maximilians Fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas
KR102671166B1 (ko) * 2015-12-14 2024-05-31 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 3,5-디페닐-디아졸 화합물의 수용성 유도체

Also Published As

Publication number Publication date
KR20240155237A (ko) 2024-10-28
EP4486340A1 (en) 2025-01-08
AU2023227368A1 (en) 2024-07-18
CN118715010A (zh) 2024-09-27
US20250161273A1 (en) 2025-05-22
JP2025508912A (ja) 2025-04-10
IL314952A (en) 2024-10-01
WO2023166045A1 (en) 2023-09-07
PE20250781A1 (es) 2025-03-14
CL2024002379A1 (es) 2025-01-24
CA3246018A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
BR112023020442A2 (pt) Inibidor da protease 1 específica de ubiquitina (usp1)
DOP2025000288A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
AR047070A1 (es) Derivados de difenilazetidona
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
AR047928A1 (es) Derivados de tetrahidropiridoindol
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
MX2024013019A (es) Compuestos de heteroarilo para el tratamiento del dolor
UY28691A1 (es) Derivados de difenilazetidona
ECSP088246A (es) Nuevos derivados de benzotiazolona
BR0315580A (pt) Derivados de metileno uréia
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
BR112021011325A2 (pt) Derivados de rapamicina
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
SA522431498B1 (ar) مشتقات 3، 6-داي أمينو-بيريدازين-3-يل، تركيبات صيدلية تحتوي عليها واستخدامها في صورة عوامل مساعدة على تلاشي الخلايا
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém